Understanding the Asthma Trial Landscape in the United States
The U.S. is home to one of the most active asthma research ecosystems in the world. As of 2026, there are dozens of actively recruiting trials spanning everything from novel biologic therapies to digital self-management interventions. Major pharmaceutical companies like AstraZeneca, Eli Lilly, and Connect Biopharma are running Phase II through Phase IV studies across all 50 states. The American Lung Association operates the nation's largest nonprofit clinical research network dedicated to asthma and COPD, with centers in Arizona, Illinois, New York, North Carolina, and Vermont.
What has changed recently is the expansion of eligibility. Historically, trials were narrow in scope — mostly adults with classic allergic asthma and high eosinophil counts. Today researchers are actively recruiting populations that were previously overlooked. The PASSAGE study, for example, specifically enrolled Black and African American participants, adolescents aged 12 to 17, people with a smoking history of 10 or more pack-years, and those with overlapping COPD features. This deliberate broadening reflects a growing recognition that asthma affects different communities in different ways and treatments need to be tested accordingly.
If you are wondering whether a trial is right for you, the question typically starts with your current level of asthma control. Most studies recruit people whose asthma remains uncontrolled despite using maintenance medications — think daily inhaled corticosteroids with or without a long-acting beta-agonist. Some trials look for patients with frequent exacerbations, defined as two or more courses of oral steroids in the past year. Others target specific biomarkers like blood eosinophil counts above a certain threshold. There is no single profile that fits all trials, which is precisely why searching broadly matters.
How the Process Actually Works
The journey from curious patient to enrolled participant follows a predictable rhythm. After identifying a trial that matches your general profile — more on how to find one shortly — you will undergo a screening visit. This is not a commitment. Think of it as a two-way interview where the research team evaluates whether you meet the inclusion criteria and you evaluate whether the study fits your life.
During screening, expect lung function testing like spirometry, blood draws to check eosinophil levels and general health markers, a review of your medication history, and a physical exam. Some studies require a bronchial challenge test to confirm airway hyperresponsiveness. If you qualify, you sign an informed consent document that outlines every procedure, visit schedule, potential risk, and your right to withdraw at any time without penalty. This document is detailed — often 15 to 25 pages — and you should read it thoroughly and ask questions before signing.
Once enrolled, the structure depends on the trial phase. Phase III studies, which are the most common type patients encounter, typically randomize participants into two or more groups: one receiving the investigational treatment and another receiving either a placebo or an existing standard therapy. You will not know which group you are in, nor will the study team in most cases. Visits might be weekly at first, then taper to monthly or quarterly over a span of 12 to 65 weeks depending on the protocol. Between visits, you may be asked to keep a symptom diary, track peak flow readings, or answer surveys about your quality of life.
Compensation varies by study but is a standard part of the arrangement. Most trials reimburse for time and travel, with amounts reflecting the burden of in-person visits rather than acting as an incentive to take risks. Some longer studies offer stipends that reach into the low thousands over the full participation period. The investigational medication, all study-related lab work, and the extra clinical attention are provided at no charge to you. You continue seeing your regular doctor for everything else.
Finding Trials That Fit
The most reliable starting point is ClinicalTrials.gov, a federal database maintained by the National Library of Medicine. You can filter by condition (asthma), location (by city, state, or ZIP code radius), study phase, and recruitment status. Searching "asthma" and "recruiting" in your state will surface dozens of options. The advanced search tool lets you narrow by age group, sex, and specific eligibility criteria.
Beyond the federal database, the American Lung Association maintains a curated list of studies through its Airways Clinical Research Centers network. Their locations include the University of Arizona in Tucson, Northwestern University in Chicago, Mount Sinai in New York, Duke University in North Carolina, and the Vermont Lung Center. Each center has a dedicated research coordinator who can walk you through open studies over the phone. Private organizations like the Allergy & Asthma Network and the Asthma and Allergy Foundation of America also publish trial listings and offer patient navigation support.
Academic medical centers and large hospital systems often host their own research registries. If you live near a teaching hospital — think UCLA, Johns Hopkins, Cleveland Clinic, or Mayo Clinic — check their pulmonary or allergy department websites. Many have a "Research" or "Clinical Trials" tab where you can browse active studies and sign up for notifications when new ones launch. Some even maintain databases where you submit your contact information once and get matched to future trials automatically.
A quick word on timing: trial recruitment moves in cycles. Some studies fill within weeks of opening, while others extend enrollment over multiple years. If you find a study that interests you, contact the coordinator promptly. Even if you do not qualify for that particular trial, the coordinator may know of other studies at the same site that could be a better fit.
Types of Asthma Trials You May Encounter
| Trial Category | Example | Typical Duration | Ideal Candidate | Key Benefit | Key Consideration |
|---|
| Biologic Therapy | Monoclonal antibodies targeting TSLP or IL-5 pathways | 24–52 weeks | Moderate-to-severe uncontrolled asthma with eosinophilic phenotype | Access to next-generation biologics before FDA approval | Requires regular injections; risk of allergic reaction |
| Triple-Therapy Inhaler | Single-inhaler ICS/LABA/LAMA combinations | 12–26 weeks | Adults with persistent symptoms on dual therapy | Simplified regimen in one device | May need to pause current medications during run-in |
| Oral Small Molecule | Brenipatide or roflumilast-based studies | 24–65 weeks | Patients with elevated BMI and poor control | Pill form rather than injection or inhalation | More systemic exposure than inhaled treatments |
| Digital/Behavioral | App-based self-management or care coordination | 3–12 months | Children and adults in urban settings | No medication changes; focuses on education and monitoring | Less direct clinical benefit during study period |
| Step-Down Strategy | Tapering maintenance therapy after biologic initiation | 12–18 months | Patients stable on biologics | Potential to reduce medication burden | Risk of temporary loss of control during tapering |
This table captures the range of study designs you will encounter. The biologic category has grown especially fast in recent years. Tezepelumab, which targets TSLP at the top of the inflammatory cascade, gained its asthma indication after the KALOS and LOGOS trials and continues to be studied in real-world settings like the PASSAGE trial mentioned earlier. Meanwhile, Brenipatide from Eli Lilly represents a newer oral option being tested in patients whose moderate-to-severe asthma remains uncontrolled on standard therapy.
What Separates a Good Trial Experience from a Frustrating One
The difference often comes down to logistics and communication. Before enrolling, ask the study coordinator practical questions: How many total visits are required? Are any of them overnight stays? Can any follow-ups be done virtually or by phone? What happens if you miss a visit? How quickly can you reach someone if you have a concern on a weekend?
Also worth asking about is the post-trial plan. Some studies offer an open-label extension phase where all participants, including those originally on placebo, receive the active treatment after the main trial concludes. Others provide no continued access, meaning you return to standard care once the study ends. This is not necessarily a dealbreaker, but knowing upfront helps manage expectations.
Transportation can be a hidden barrier. If the study site is two hours away and visits are weekly for the first month, that adds up fast. Some research centers help with travel logistics or partner with ride services. Others provide prepaid cards for gas or parking. Ask about this during screening rather than discovering it mid-trial.
Your regular doctor should be kept in the loop. Most trial protocols require participants to have a primary care provider or pulmonologist who manages their overall asthma care outside the study. The research team handles everything related to the investigational treatment, but they do not replace your usual healthcare. Good communication between the two sides prevents gaps in care — for instance, if you need antibiotics for a respiratory infection while on a trial, both teams need to know.
Medical privacy is governed by HIPAA in the U.S., and trial data is anonymized before publication. Your name never appears in study results. The informed consent form will spell out exactly how your information gets used, stored, and shared.
Taking the Next Step
Start with ClinicalTrials.gov and plug in your city or region. Then cross-reference with the American Lung Association's ACRC network if a center is within driving distance. Talk to your pulmonologist or allergist — they may know of studies recruiting at their own institution or can help you evaluate whether a trial's eligibility criteria align with your medical history.
When you call a research site, have a few details ready: your current medications and doses, approximate number of exacerbations in the past year, most recent lung function test results if available, and whether you have been hospitalized for asthma. This helps the coordinator quickly assess whether you fit the basic profile.
Thousands of Americans participate in asthma trials each year, and the overwhelming majority report positive experiences regardless of whether they received the active treatment. The medical attention is thorough, the financial burden is minimal, and the contribution to advancing asthma care is real. The hard part is taking the first step — finding a study and making that initial phone call.
研究の知恵